Targeting Hypermutable ‘superbugs’ In Chronic Respiratory Infections By Optimised Antibiotic Combination Dosage Regimens
Funder
National Health and Medical Research Council
Funding Amount
$697,731.00
Summary
Many bacterial ‘superbugs’ can increase their mutation rate, i.e. become hypermutable, and thus rapidly become resistant to multiple antibiotics. Chronic lung infections with hypermutable bacteria cause increased ill-health and death in patients and current treatments do not work well. We will develop improved treatments using combinations of available antibiotics. This project will provide guidance to doctors on how to treat infections more effectively and minimise emergence of resistance.
Developing Irreversible Electroporation Non-Thermal Tumor Ablation For Organ-Confined Prostate Cancer Treatment
Funder
National Health and Medical Research Council
Funding Amount
$290,512.00
Summary
IRE is technique for targeted tissue ablation. Electrodes placed into the targeted area deliver intense, brief electric pulses. Nano-scale pores are created in the cell membrane killing the cells but preserving the extracellular matrix. The pulses do not affect sensitive structures including neurovascular bundles, major vasculature and ductal systems preserving their function. It may address prostate regions implicated in prostate cancer without damaging vital structures, reducing side effects.
Optimisation Of The Safety And Efficacy Of Protein Kinase Inhibitors Using Endogenous And Dietary Biomarkers
Funder
National Health and Medical Research Council
Funding Amount
$384,360.00
Summary
Many new cancer medicines are part of the 'kinase inhibitor' group of drugs. Although these drugs are effective in treating a range of different cancers, opportunities remain to improve the effectiveness and safety by more intelligently deciding the dose of the drug that a specific individual should receive. The research aims to assess whether the levels of chemicals normally present in the blood of individuals being treated can be used to guide the best dose an individual should receive.
The Pharmacokinetic, Pharmacodynamic And Pharmacogenomic Outcomes Of Reduced Dosage Of Efavirenz: The Encore1 Study
Funder
National Health and Medical Research Council
Funding Amount
$1,234,943.00
Summary
Our primary aim is to assess blood concentrations of a drug called efavirenz, an important drug used in the treatment of HIV infection and associate these with variability of genes that control metabolism of the drug. A better understanding of gene variability and how it relates to safety and efficacy outcomes at a reduced, compared to a standard dose of efavirenz could support improved treatment of HIV disease.
First Ever System To Continuously And Directly Measure The Internal Anatomy To Guide Breast Cancer Radiation Treatment Under Deep Inspiration Breath Hold
Funder
National Health and Medical Research Council
Funding Amount
$409,766.00
Summary
We propose a first ever system to continuously and directly measure the internal anatomy of the patient during radiotherapy of left sided breast cancer to ensure correct position of patient and radiation beam. The proposed method involves no additional radiation dose to the patient. It relies on existing components of modern radiation treatment machines, requiring no additional equipment, which will make it easy to implement widely.
Improving Radiation Therapy Of Static And Moving Targets Using High Spatial Resolution Real-time Dosimeters
Funder
National Health and Medical Research Council
Funding Amount
$544,425.00
Summary
Radiation therapy is a major oncology modality for cancer treatment and more than 50% of cancer patients can benefit from radiotherapy at some stage of management. This project will develop two real-time, high spatial resolution dosimetry systems for quality assurance of contemporary radiation treatments of static and movable targets. It will be possible to minimize human and robotic system error so as to guarantee accurate cancer treatment delivery and improve the clinical outcomes of radiother ....Radiation therapy is a major oncology modality for cancer treatment and more than 50% of cancer patients can benefit from radiotherapy at some stage of management. This project will develop two real-time, high spatial resolution dosimetry systems for quality assurance of contemporary radiation treatments of static and movable targets. It will be possible to minimize human and robotic system error so as to guarantee accurate cancer treatment delivery and improve the clinical outcomes of radiotherapy.Read moreRead less
Monitoring Changes In CT Scanning Usage To Minimise Cancer Risk?
Funder
National Health and Medical Research Council
Funding Amount
$604,664.00
Summary
Computed tomography scanning (CT) is an x-ray technique that uses ionizing radiation to produce the images of the body. Ionizing radiation is harmful and carries a risk of cancer. Concerns have been expressed about the increasing use of CT with the importance of monitoring the trends in use recognised internationally. We will investigate changes in the use of CT, estimate the radiation dose and the number of cancers that can be expected due to CT.
Novel Prolonged-release Polymeric Microparticles For Relief Of Intractable Cancer-related Pain
Funder
National Health and Medical Research Council
Funding Amount
$796,950.00
Summary
For the 10-30% of patients with advanced cancer who experience intractable pain despite administration of large doses of morphine-like drugs by mouth or injection, more invasive dosing routes may be needed. This project will utilise innovative polymer chemistry to develop bioerodable prolonged-release polymer microparticles to deliver pain-killers into the spinal fluid near to the cells that mediate their actions, with a view to producing prolonged periods of analgesia in these patients.
REVEALING MOLECULAR MECHANISMS OF THE SYNCHROTRON RADIATION-INDUCED BYSTANDER EFFECT
Funder
National Health and Medical Research Council
Funding Amount
$429,294.00
Summary
Radiotherapy, a major treatment for more than half of cancer patients, is based on the dogma that radiation kills targeted cells. The radiation-induced bystander effect, by which the neighbours of irradiated cells can also damaged, is a new paradigm. What is the "danger signal" which induces DNA damage in un-irradiated normal tissues, and what minimal volume of tissue needs to be irradiated to induce bystander damage? The answers could have a major impact on optimising radiotherapy treatment.